



New trends in diagnosis and management of gastroenteropancreatic neuroendocrinal tumors (GEP-NETs)

An Essay

Submitted for partial fulfillment of Master Degree in General Surgery

By

Islam Mohammad Mohammad Hegazy

(M.B.B.Ch)

Ain Shams University

Under Supervision of

Prof. Awad Hassan Alkayal M.D.,

Professor of General Surgery

Faculty of Medicine-Ain Shams University

Abdelkarem Zaid M.D.,

Fellow of General Surgery

El-Demerdash hospital

Faculty of Medicine-Ain Shams University

**Faculty of Medicine
Ain Shams University**

2012

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قالوا

سببنا أنك لا تعلم لنا
إلا ما علمتنا إنك أنت
العليم العظيم

صدق الله العظيم

سورة البقرة الآية: ٣٢

Acknowledgements

First, thanks are all directed to ALLAH for helping me to accomplish this research, and for providing me with such very encouraging and supportive supervisors.


I would like to express my deepest gratitude to Prof. Dr Awad Hassan Alkayal, Professor of General Surgery, Faculty of Medicine, Ain Shams University, for his great support and continuous encouragement throughout the whole work under his guidance and supervision.

My deepest appreciation and grateful thanks are due to Dr. Abdelkarem Zaid Fellow of General Surgery, Faculty of Medicine, Ain Shams University, for his kind advices and his great effort throughout this work.

Also, I cannot fully express my deep gratitude and thanks to my wife and my daughter(Nourin), who I loved a lot and to whom I dedicate this work, and to all my family and I dedicate this work to the souls of my parents.



DR.Islam Mohammad Hegazy



Contents

<u>Abbreviations</u>	i
<u>List of figures</u>	iv
<u>List of tables</u>	viii
<u>Aim of the work</u>	x
<u>Introduction</u>	xi
<u>Chapter 1: Development, embryology and cell biology of GEP-NETs.</u>	1
<u>Chapter 2: Pathophysiology of neuroendocrine tumors</u>	8
1-Secretory function of the neuroendocrine cell phenotypes:	
2-etiology and pathogenesis	
3-staging and classification of GEP-NETs	
<u>Chapter 3: Clinical presentation of GEP-NETs</u>	42
A-carcinoid syndrome	
B- Neuroendocrine tumors in specific sites:	
1-Luminal gastrointestinal NETs:	
2-Pancreatic NETs:	
<u>Chapter 4: Diagnosis of neuroendocrine tumors</u>	66
1-Biochemical measurements:	
2-Imaging techniques:	
<u>Chapter 5: Treatment of NETs</u>	110
A-Surgical treatment	
B-Medical treatment of NETs:	
C-Treatment of Neuroendocrine Liver Metastases	
<u>References</u>	143
<u>Summary and conclusion</u>	153
<u>Arabic summary</u>	156

List of abbreviations

5FU	5flurouracil
5-HT	5-hydroxytryptophan,
5-HIAA	5-hydroxyindoleacetic acid
AADC	Aromatic acid decarboxylase
ACTH	Adrenocorticotrophine releasing hormone
AJCC	American Joint Cancer Committee-
APC	Adenomatous polyposis coli
BAO	Basal acid out- put
bFGF	Basic fibroblast growth factor
bHLH	Basic helix-loop-helix
CAG	Chronic atrophic gastritis
CCK	Cholecystokinin
CgA	Chromogranin A
CgB	Chromogranin B
CHD	Carcinoid heart disease
CK	Cytokeratin
CNC	Carney complex
CRH	Corticotrophic releasing hormone
CT	Computed tomography
DAT	Dopamine transporter
DEB-TACE	Drug-eluting beads transarterial chemoembolization
DMSA	Dimercaptosuccinic acid
DNES	Diffuse neuroendocrine system
DOPA	Di-hydroxy-phenylalanine
DSA	Digital subtraction angiography
DTPA	Diethylene triamine-pentaacetic acid
EC	Enterochromaffin cells
ECL	Enterochromaffin like cells
EGFR	Epidermal growth factor receptor
ENETS	European NeuroEndocrine Tumors Society
EUS	Endoscopic ultrasonography
FDG	Fluor-2-deoxy-d-glucose
FNA	Fine-needle aspiration
FSG	Fasting serum gastrin
GEP-NETs	Gastroentero-pancreatic neuroendocrine tumors
GH	Growth hormone
GIP	Gastric inhibitory peptide
GLP	Glucagon-like peptide
GRF	Growth hormone releasing factor
GRP	Gastrin-releasing peptide

List of abbreviations

HPF	High power field
HPT	Hyperparathyroidism
IBS	Inflammatory bowel syndrome
ICC	Immunocytochemistry
IFN	Interferon
IGF1	Insulin-like growth factor 1
IHC	Immunohistochemistry
IOUS	Intraoperative ultrasound
LAR	Long-acting repeatable
LAT	Large amino acid transporter system
LDCV	Large dense-core vesicles
MANEC	Mixed adenoneuroendocrine carcinomas
MCT	Medullary carcinoma of the thyroid
MDCT	Multidetector CT
MDR-1	Multi-drug resistance gene 1
MEEC	Mixed exocrine–endocrine carcinoma
MEN I	Multiple endocrine neoplasia type I
MIBG	Metaiodobenzylguanidine
MRI	Magnetic resonance imaging
mTOR	Mammalian target of rapamycin
NECs	Neuroendocrine carcinomas
NENs	Neuroendocrine neoplasia
NETs	Neuroendocrine tumors
NF-I	Neurofibromatosis type I
NF-PNETs	Nonfunctional Pancreatic NETs
NGN	Neurogenin
NKA	Neurokinin A
NSE	Neuron Specific Enolase
NSF	N-ethylmaleimide-sensitive fusion protein
PACAP	Pituitary adenylate cyclase activating peptide
PAX	Paired box gene
PDECs	Poorly differentiated endocrine carcinomas
PDGF	Platelet-derived growth factor
PET	Positron emission tomography
PP	Pancreatic polypeptide
PPIs	Proton pump inhibitors
PRRT	Peptide receptor radionuclide therapy
PTEN	Phosphatase and tensin homolog
PTH	Parathyroid hormone
PTH-rP	Parathyroid hormone related peptide
PUD	Peptic ulcer disease
PVA	Polyvinyl alcohol

List of abbreviations

RFA	Radiofrequency ablation
SLMV _s	Synaptic-like microvesicles
SNAP-25	Synaptosome-associated protein
SNARE	Synaptosomal-associated protein receptor
SpDP	Spleen-preserving distal pancreatectomy
SPECT	Single photon emission computed tomography
SRS	Somatostatin receptor scintigraphy
SSTR _s	Somatostatin receptors
SSV	Small synaptic-like vesicles
STZ	Streptozotocin
TACE	Transarterial chemoembolization
TAE	Transarterial bland embolization
TCF	T cell factor
TK	Tyrosine kinase
TKIs	Tyrosine kinase inhibitors
TLL	Tumour-like lesions
TSC	Tuberous sclerosis
t-SNARE _s receptor	Target membranes synaptosomal-associated protein
u5-HIAA	Urinary 5-hydroxyindoleacetic acid
UGI	Upper gastrointestinal
UICC	Union Internationale Contre le Cancer
VAMP	Vesicle-associated membrane protein
VCE	Videocapsule endoscopy
VEGF	Vascular endothelial growth factor
VHL	von Hippel-Lindau syndrome
VIP	Vasoactive intestinal polypeptide
VMAT	Vesicular monoamine transporter
v-SNARE _s receptor	Vesicle membrane synaptosomal-associated protein
WCE	Wireless capsule endoscopy
WDET	Well-differentiated endocrine tumour
WDHA	Watery Diarrhea, Hypokalemia, and Achlorhydria
WDNEC	Well differentiated neuroendocrine carcinoma
ZES	Zollinger-Ellison Syndrome

List of figures

<u>Figure No.</u>	<u>Title</u>	<u>Page</u>
<u>Fig.1</u>	Neuroendocrine cell differentiation in the gastrointestinal tract. Basal crypt stem (totipotent and pluripotent) cells give rise to a variety of mucosal cell types: Math1 expression directs cells to the secretory lineage and NGN3 to the neuroendocrine lineage. Specific hormone transcription is regulated by several transcription factors such as Pax4, Pax6, and BETA2.	2
<u>Fig.2:</u>	Schematic overview of enteroendocrine differentiation in the intestinal tract. Stem cells located in the crypts differentiate into all four cell types present in the intestinal epithelium. Math1 expression restricts cells to the secretory lineage and NGN3 restrict cells to the endocrine lineage, whereas the transcription of specific hormones is regulated by several late acting transcription factors such as Pax4, Pax6 and BETA2.	6
<u>Fig.3</u>	Calcium-dependent exocytosis. CgA is a key protein in the genesis of vesicles and regulates the biogenesis of dense-core secretory granules. Secretory products are stored in large dense-core vesicles (LDCV) and in small synaptic-like vesicles (SSV). Proteins associated with these vesicles (e.g., CgA or synaptophysin) have been utilized as biomarkers of neuroendocrine cells. Prohormones and proneuropeptides are stored and processed in the trans-Golgi network prior to packaging into secretory granules (LDCV) as bioactive peptides for regulated secretion.	11
<u>Fig.4</u>	Mechanism of vesicle docking and exocytosis at the plasma membrane. SNAREs have been identified both on the vesicle membrane (v-SNAREs) and on target membranes (t-SNAREs). The docking site is formed by the tight binding of one v-SNARE, synaptobrevin or vesicle associated membrane protein (VAMP), with two t-SNAREs, syntaxin and synaptosome-associated protein (SNAP-25), resulting in a stable trimeric core complex. At the completion of docking, vesicle content is released into the paracellular space.	12
<u>Fig.5</u>	Transformative events (putative) in the development of GEP-NETs. NETs develop in inherited/familial tumors of the stomach (gastric type II) and pancreas (pNETs) as a consequence of either a second hit or LOH somatic mutations, the most common event, perhaps due to environmental damage at a committed neuroendocrine precursor stage, lead to well-differentiated NETs (NET-G1). If damage occurs early in stem cell progress	14

List of figures

	(e.g., stem cell 1), poorly differentiated neuroendocrine carcinomas develop. If damage occurs at a later stage, for example to a pluripotent cell (stem cell 2), then a well-differentiated NEC (G2-NET) is the consequence. There is little evidence for evolution from a NET to a NEC in this schema.	
<u>Fig.6:</u>	Gastric NET (ECL cell) pathogenesis. The physiological regulation of acid secretion (top) involves luminal amino acid activation of G-cell gastrin secretion to provoke fundic ECL cell histamine release, which stimulates parietal cell acid secretion. Luminal acid increase counter-regulates gastrin via a somatostatin-modulated negative feedback loop. In Type I gastric tumors (left), diminution of parietal cell function (e.g., pernicious anemia or atrophic gastritis) increases luminal pH which stimulates gastrin secretion and sustained hypergastrinemia, culminating in ECL cell proliferation. This growth proceeds through phases of hyperplasia, dysplasia, and neoplasia. In Type II lesions (right), hypergastrinemia originates from autonomous secretion by a gastrinoma (G-cell neoplasia). In type III tumors (bottom), neoplastic transformation occurs independently of gastrin levels.	17
<u>Fig.7</u>	Well-differentiated neuroendocrine neoplasms of the stomach: (a) Multiple small polypoid tumours in the corpus region of the stomach associated with chronic atrophic gastritis of the oxyntic mucosa (type 1 gastric NET). (b) ECL cell hyperplasia in the oxyntic mucosa with microtumours. (c) ECL cell hyperplasia in patients with MEN-I. (d) Type 3 NEN of the stomach with infiltration of muscular wall.	20
<u>Fig.8</u>	Well-differentiated neuroendocrine tumour of the duodenum producing gastrin. Duodenal mucosa showing a small submucosal tumour.	21
<u>Fig.9:</u>	Gangliocytic paraganglioma showing triphasic cellular differentiation: Ganglion cells (center), endocrine cells (left) and Schwann cells (right).	22
<u>Fig.(10):</u>	(A) Gastric neuroendocrine tumor seen in the gastric fundus on endoscopy and (B) endoscopic ultrasound of the same lesion (arrow). Note that the lesion invades all layers of the gastric wall but does not erode through the adventitia.	81
<u>Fig.(11):</u>	immunocytochemistry ICC chromogranin-A+ve.	81
<u>Fig.(12):</u>	A, B, C; Submucosal mass in the ileum, finally diagnosed as a small-intestinal carcinoid tumor in 3 different patients. D; Ischemic small intestinal segment from external	83

List of figures

	compression by a mesenteric carcinoid tumor.	
<u>Fig.(13):</u>	Well-differentiated endocrine carcinoma of the duodenum in an 82-year-old man. A The CT image shows enlargement of the ampulla of Vater. The density of the wall is homogeneous, and the lumen of the duodenum is dilated. B Arterial phase image: the thickened wall is homogeneously and moderately enhanced. C The axial and D coronal images show the lesion is further enhanced in the venous phase. Intrahepatic bile duct and the common bile duct are dilated.	84
<u>Fig.(14):</u>	A-Transaxial CT image during i.v. contrast enhancement in the portal-venous inflow phase of several well-vascularised midgut carcinoid liver metastases. B- In the venous phase the metastases are no longer discernible.	85
<u>Fig.(15)</u>	Coronal T 2 -weighted MR Endocrine Pancreatic Tumor in the pancreatic head. The common bile duct can be clearly delineated and is not compromised by the tumor.	87
<u>Fig(16):</u>	Transaxial, sagittal, and coronal cross-sectional computed tomographic (CT) and nuclear images in hindgut NETs. Top panel, Multi-phasic thin-section CT images with oral contrast demonstrating metastatic nodal disease in the left panel (transaxial), middle (sagittal), and right (coronal) panels. Lower panel, ¹¹¹ In-diethylene triamine pentaacetic acid octreotide scintigraphy with CT fusion demonstrating somatostatin receptor 2 and/or 5 bearing tumor (liver and lymph nodes) in the same patient.	92
<u>Fig(17):</u>	Cross-sectional and nuclear imaging in midgut NETs. Left, Multiphasic thin-section CT with negative oral contrast demonstrates primary ileal NETs with regional nodal disease and liver metastases. Right, [¹¹¹ In-DTPA0] octreotide scintigraphy with CT fusion demonstrating somatostatin receptors 2 and/or 5 bearing tumor in the same patient.	93
<u>Fig.(18):</u>	Metastasized carcinoid. ¹⁸ F-DOPA PET scans (A), octreotide scan (B) and ¹⁸ F-DOPA PET-CT fusion image (C) of a female patient presenting with a metastasized carcinoid. This patient illustrates the intra-individual heterogeneity in the uptake of different tracers by tumor metastases (arrows).	100
<u>Fig(19):</u>	Patient in whom the 3 imaging modalities were in agreement with each other, finding large focus in liver. Origin of primary tumor and liver metastases was unknown. Ki67 index was 10%. From left to right are CT images; ¹⁸ F-FDG PET (top), ¹²³ I-MIBG scintigraphy (middle), and SRS (bottom) images; and fused images.	106
<u>Fig (20):</u>	Algorithm for the investigation of neuroendocrine tumours (NETs). ACP, Acid Phosphatase; BNP, brain natriuretic peptide; CgA, chromogranin A; EUS, endoscopic ultrasound; FDG, fluorodeoxyglucose; GI,	109

List of figures


	gastrointestinal; GPCA, gastric parietal cell autoantibody; HCG, human chorionic gonadotrophin; 5HIAA, 5-hydroxyindoleacetic acid; 5HTP, 5-hydroxytryptophan; MEN-1, multiple endocrine neoplasia 1; MIBG, metaiodobenzylguanidine; NF, neurofibromatosis; PET, positron emission tomography; PP, pancreatic polypeptide; PTH, parathyroid hormone; VHL, Von Hippel Lindau.	
<u>Fig.21</u>	Intraoperative findings with ultrasonography. The main pancreatic duct can be clearly detected by a polyethylene stent in a tumor located very close to the main pancreatic duct (<i>MPD</i>), and it is easy to determine the relationship between the tumor (<i>T</i>) and main pancreatic duct.	117
<u>Fig.22</u>	Several strings are placed on the pancreas parenchyma in front of the tumor, like a parachute. These strings are used for traction.	117
<u>Fig.23</u>	The surgeon's index finger compresses the tumor from behind. This compression and traction by parachute strings widens the space between the tumor and pancreatic parenchyma. Detachment and dividing are performed in the wide surgical field between the tumor and pancreatic parenchyma.	117
<u>Fig.(24):</u>	CT of bilobar hepatic metastases from a malignant NET in the (a) arterial phase and (b) venous phase. The characteristic enhancement of the tumor on arterial phase is apparent, as well as the relative darkening of the tumor on venous phase; the area of central necrosis is dark in both phases. Note the primary NET in the tail of the pancreas.	138
<u>Fig (25):</u>	Post-TACE MRI of bilobar hepatic metastases from the same patient in the arterial phase. Note the brightness of the aorta and lack of enhancement of the lesions compared to <u>Fig.(23)</u> , indicating the ischemia produced by the embolization.	138
<u>Fig(26):</u>	(A) Algorithm for the treatment of localised or metastasised NET. The treatment depends on localisation of the primary and the proliferation index (Ki-67). Light blue boxes indicate seldom used alternatives. (B) Algorithm for interventional treatment of neuroendocrine liver metastases.	142

List of tables

<u>Table No.</u>	Title	<u>Page</u>
<u>Table 1</u>	Distribution and Actions of the Common Neuroendocrine Cells and Enteric Neuropeptides Involved in Neuroendocrine Pathology.	9
<u>Table 2</u>	T, N and M categories in the ENETS TNM classification of pancreatic neuroendocrine tumors.	35
<u>Table 3</u>	Grading for pancreatic and other digestive neuroendocrine tumours, according to ENETS/TNM.	35
<u>Table 4</u>	TNM classification for gastric endocrine tumors.	36
<u>Table 5</u>	TNM classification for endocrine tumors of the appendix.	36
<u>Table 6</u>	Disease staging of gastroenteropancreatic NETs.	37
<u>Table 7</u>	TNM classification for endocrine tumors of colon and rectum.	37
<u>Table 8</u>	TNM categories in the UICC/AJCC TNM classification of pancreatic neuroendocrine tumors.	39
<u>Table 9</u>	Comparison of WHO 2010 classification for gastroenteropancreatic neuroendocrine neoplasms with previous WHO classifications.	41
<u>Table 10</u>	Clinical features of GEP-NETs.	42
<u>Table 11</u>	Common symptoms and signs of the main neuroendocrine tumor syndromes.	43
<u>Table 12</u>	Potential clinical symptoms based on carcinoid tumor location.	49
<u>Table 13</u>	Clinical presentation, syndrome, tumor type of ectopic pancreatic tumors, and the hormones produced.	61
<u>Table 14</u>	The Frequency (%) of General Manifestations and of Different Types of Pancreatic Endocrine Tumors in Patients With Multiple Endocrine Neoplasia Type-I.	64
<u>Table 15</u>	Foods and Medications to Be Avoided During 5-HIAA Collection.	70
<u>Table 16</u>	Peptide markers specific to the tumour site.	71
<u>Table 17</u>	Conditions associated with hypergastrinemia.	73
<u>Table 18</u>	Common symptoms, signs diagnostic criteria of the main Neuroendocrine Tumor Syndromes.	74

List of tables

<u>Table 19</u>	Sensitivities (%) of various imaging techniques.	88
<u>Table 20</u>	Medical and preoperative treatment for Neuroendocrine Tumors.	111



Aim of the work